Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't Want to Mention It --- Would Be "Pumping"
My Scientific Reasons....
Just Bought My Last Shares
I'm all-in; bought my last tranch of AVXLs a bit earlier this morning. Nice gains are now posting.
I'm a small-time retail stock investor, buy shares of equities for which I know their stories; with the moderate amounts of discretionary investments cash in my family budget. Presently, I have positions with only two companies, the far larger and more promising is Anavex Life Sciences Corp. For Anavex I've been accumulating shares for over five years, and at this very moment have a 244% value gain in my AVXL position.
As a biologist I know and understand the science of Anavex's drug molecules. Consequently, I intend to hold my AVXL position and only take dividends when they start to appear in a few years. I'm in my 70s, and when I croak, probably in my 80s (maybe longer if I can take blarcamesine for anti-aging prophylaxis) the entire position will go to my estate beneficiaries, my wife, my children, and a few select philanthropies.
I thank those who have frequently posted technical analysis perspectives; they have helped in my buys. All have been gains. now, I just sit back and watch what happens to Anavex Life Sciences Corp in the next few months, then the next five years. I'll refrain from positing anything regarding share prices and share purchases. On out, it'll be the world's recognition and implementation of Anavex science. Another world....
You Can Be My Physician
Favorable Expectations; Will Be Buying More
Blarcamesine, for Insomnia, would make Anavex a success.
Again, Anavex 3-71.
Persisting Efficacies
The Study is Purely Academic
This new study to help determine if beta-amyloid and tau tangles are the root causes of Alzheimer's may help determine that they actually aren't; that they are merely present but are not the root or primal causes of the disease.
Effectively, the results of the study aren't likely to change things very much for patients with the disease. The findings will be essentially academic; of little practical application.
What there really needs to be is a study of something new that shows useful suppression, reversal, or prevention of Alzheimer's symptoms. That would be really important.
Wait a minute.... Something like that might pop up on December 1.
Dieouts vs Dropouts
The Quiet Science First, Then the Transforming News
Anavex Science Hasn't Changed Perceptions, Yet.
No, Science Doesn’t Speak. News Media Will Speak.
"Sufficient" Will Be A Better Term
Amyloid-beta42 Shrinks the Brain in Parkinson's Disease
It Means, Parkinson's Therapies Are Complex
New Geriatric Dementia and Cognition Metrics
Nothing really wild about "wildtype."
Bold Projection
I'm going way out on a flimsy limb:
More than one million shares of AVXL will be traded today.
One of the first FUDstration warnings.
Couldn't Resist --- Buying More
In the last eight years I've taken and held three penny-stock positions, all with discretionary funds. Knew from the start that any or all could fail; that I could lose my invested dollars.
Well, my investment in AVXLs has appreciated very nicely. For the several thousand Anavex shares I own my base price cost is $2.91. I'm up over 300% --- and, now, de-risked.
One of my other penneys is essentially worthless. I'll hold it and then claim it as a tax loss.
But I just sold off half of my final penny stock holding. It was still slightly in the red, but has firm potential. So, I sold off half of that holding and now have a few more thousands of dollars to increase my AVXL holding with. Will be buying when that stock sale clears, in next Tuesday.
I'm putting my money where my postings have been; with Anavex Life Science Corp. Talk (on a message board) is cheap, even if truthful. Hope others can board the AVXL train. It's still at the station, but the "All Aboard" whistle has just sounded. Get your tickets and jump on board.
New AVXL Purchase
As readers know, I've been a long-time believer in the Anavex science and its unique, revolutionary mechanism of action (propitious activation of the sigma-receptor, thereby facilitating all sorts of favorable downstream processes in the neuron).
As a retired biology teacher I live comfortably on my moderate teacher's pension. But unlike other posters, I don't have many thousands of dollars to buy thousands of AVXLs. Over the years I've incrementally accumulated a position of several thousand. Just now I've instructed my bank to send a few thousand dollars from my checking account to my Charles Schwab account. It should be there on Oct 19, after which I'll be expanding my Anavex holding.
My best wishes, now, to everyone. I find that any holding in AVXL shares (other than a short position --- best wishes to those who don't cover right away) is essentially de-risked. On out, it's onward and upward.
Next, What Gets Reported, And What Happens?
Right now, except for the very few who scrutinize the information on this message board and the listings in the CTAD program, no one else in the general public knows that Anavex will be presenting, revealing top line data from their big, long placebo-controlled clinical study of blarcamesine tested on people with early-stage Alzheimer’s.
It will be interesting to see how the media react and write about Anavex’s short presentation. Before that, Anavex very likely will post details of the clinical results. How will those data and findings be presented in the news media? “Anavex Drug Shows Great Promise for Alzheimer’s.” Or, “New Alzheimer’s Drug With Unknown Chemistry Will Need New Studies.”
From the start (now, many years ago) I’ve always contended that real success for Anavex Life Sciences Corp won’t occur until the news media accurately convey to lay audiences both a) the very positive clinical outcomes from blarcamesine, and b) that those clinical results occurred absent any obviating or serious side effects. When those perspectives are laid out in the general news media (starting with defining articles in The New York Times), a diagnosis of Alzheimer’s will no longer be popularly (and accurately) regarded as the death sentence it is. The focus will be no longer on inventing or using some monoclonal antibody that digests beta-amyloid agglomerations or tau tangles; it will be on “When can we get this blarcamesine!?”
The World Doesn't Know Yet
Fifteen Minutes First, Then....
The CTAD conference schedule allocates just 15 minutes to Dr. Macfarlane to reveal, as best he can in that short interval, the top line data from the big Anavex (blarcamesine) Alzheimer’s clinical trial. The presentation is to start at 4:30, with another, unrelated presentation at 4:45.
Not much time to get into details; just a quick telling of major trial metrics. Of course, if those were weak or negative, Missling would have never decided to first present them at a CTAD conference. Nor would all the other Anavex people attending want their names listed.
At some time, probably just after the presentation, Anavex will post the details. The world will know. Everything different after that. Things being set up for all that will happen in 2023.
Economic and Social Forces for Blarcamesine Approval
Seems Existing mRNA Science Would Support Anavex
Oh, Anavex shouldn't, but Pfizer should?
Really?
Anavex’s ‘Eggs’ Will Be Clinical Results
Factors in FDA Approval of Blarcamesine
As with Aricept, a mere Slowing of Dementia
Just read the new article in Nature, titled “Alzheimer’s drug slows mental decline in trial — but is it a breakthrough?” Lots of information on the new Alzheimer’s drug and the clinical trials data used to show safety and efficacy (such as they were).
Lots of negatives noted. I’ll let other readers of the article expound on them. But for Anavex (blarcamesine) as a potential competitor against Eisai and Biogen (lecanemab), one statement seemed worthy of consideration. In the clinical trial, “Participants received intravenous infusions of either lecanemab or a placebo every two weeks for the duration of the trial.”
Treatment of Alzheimer’s with lecanemab will require patients be injected with the drug every two weeks. With blarcamesine, a pill is swallowed once a day. For your demented grandmother with Alzheimer’s which would be the preferable therapeutic regimen?
Of course, the Biogen drug “...slowed the rate of cognitive decline for people in a clinical trial by 27%.” Grandmother still had Alzheimer’s, but her cognitive decline was slowed slightly (at a yet disclosed drug purchase cost). As with Aricept, the SOC (standard of care) drug for Alzheimer’s, patients on lecanemab will continue on a lethal progression of their dementia; just more slowly.
When the blarcamesine clinical results appear for Alzheimer’s, let’s compare how patients on both drugs fare with continued therapies. With lecanemab, a very slight slowing of the progression of dementia, ultimately resulting in death. With blarcamesine? Let’s wait and see. I’ll be holding my AVXL stock position; won’t be buying any BIIB shares. I’ve seen and learned from all of the existing clinical data on both murines (lab rodents) and humans with Alzheimer’s tested with blarcamesine.
Validation by Professional Employment
But everything will be different.
Similar Price and Long-Term Value Projections
Cassava Cautions
When I first heard of Cassava Sciences, Inc, I wondered about the company; why it would elect to call itself “cassava.” In fact, “cassava” is the common name in many or most tropical countries for the Manihot esculenta plant, also known variously as manioc or yucca. The plant grows well in poor, droughty soils, creating a large starchy root; which is the source in much of the tropical world for edible carbohydrates.
But the big starchy roots must be properly prepared. “It must be properly prepared before consumption, as improper preparation of cassava can leave enough residual cyanide to cause acute cyanide intoxication, goiters, and even ataxia, partial paralysis, or death.”
If not properly prepared, by ample washing, the plant is toxic. Why would anyone want a drug company to be known for an otherwise toxic food root? Might the name indicate that the company’s drugs, like its namesake food plant could be toxic?
https://en.wikipedia.org/wiki/Cassava
Anavex Science Coupled with Patience
Dosing levels and durations.
Blarcamesine as a contra-aging agent.
Experts here after blarcamesine approval.
It is so wonderful to ponder the many posted comments on blarcamesine dosings and dosage determinations. Obviously, getting the right dose for each individual Alzheimer's patient is extremely important. Too little creates reduced or absent therapeutic results. Too much? Well....
Fortunately, when the FDA approves blarcamesine as a treatment for Alzheimer's Anavex can enlist the dosing expertise on this stock investment message board. Alzheimer's patients (and their doctors) will benefit so much.